Efficacy of sunitinib

Sunitinib (Sunitinib) is a multi-target tyrosine kinase inhibitor with anti-angiogenic and anti-tumor activities and can prolong the survival of patients with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumors (GIST). This molecule has also been reported to be associated with high rates of cardiotoxicity, but the mechanism remains unknown. In one study, sunitinib was observed to exhibit a high antiproliferative effect on H9c2 cardiomyocytes, as measured by PI staining and MTT assay.

48 hours after sunitinib treatmentApoptotic markers in H9c2 cells were all negative, suggesting that sunitinib-induced cardiotoxicity may involve another cell death pathway. Sunitinib was found to significantly increase autophagy flux in H9c2 cells. Acidic vesicle fluorescence and high expression of LC3-II in H9c2 cells identified autophagy as a sunitinib-induced process that may be related to cytotoxicity. Furthermore, knockdown of Beclin 1 by RNA interference to block autophagy in H9c2 cells showed reduced mortality when treated with sunitinib compared with control cells. These results confirm that autophagy plays an important role in sunitinib-mediated H9c2 cytotoxicity.

The original sunitinib drug has been launched in China and has entered the scope of Class B medical insurance. SpecificationsThe price of 12.5mg*28 tablets is around RMB 3,500. The original sunitinib drug has also been launched overseas. The price of 12.5mg*7 tablets is around RMB 1,500 (the price may fluctuate due to the exchange rate). There are also generic drugs produced in other countries. The price of 12.5mg*28 tablets produced by an Indian pharmaceutical factory is around RMB 750 (the price may fluctuate due to the exchange rate). The generic drugs produced abroad are basically the same as the original drugs at home and abroad. There may be differences in the prices of different specifications of drugs.